MarketInOut Stock Screener Log In | Sign Up
 

Arbutus Biopharma Corp

IEX • Healthcare • Biotechnology • Quote as of 07/31/2026
Arbutus Biopharma Corp stock price and volume chart

Company Profile

IndustryBiotechnology
SectorHealthcare
ExchangeIEX
Market Capitalization857.31 mln
Float123 mln
Earnings Date11/11/2026

EPS

0.83
Decent

P / E

5.24
Undervalued

Piotroski F-Score

5 / 9
Neutral

Beneish M-Score

31.08
Highly suspicious

1-Year Forecast

5.19
Attractive

Relative Strength

19 / 100
Significantly lagging

Business Description

Arbutus Biopharma is a clinical-stage company based in Warminster, Pennsylvania, focused on developing new treatments for chronic Hepatitis B. Its two lead drugs work in different ways ? one reduces harmful viral proteins in the body, while the other helps the immune system fight the infection more effectively. The company also holds a licensing agreement with Alnylam Pharmaceuticals to use their drug delivery technology in its products.

Key Fundamentals

EPS0.83
P/E5.24
ROE139
RPS0.98
ROIC397
ROA116
Interest Cover1,803
EBITDA, mln161
EV / EBITDA4.69
EV / EBIT4.70
Revenue, mln191
EV / Revenue3.94

Financial Strength

Altman Z-Score28.51
Piotroski F-Score 5 / 9
Beneish M-Score31.08
Price to Graham Number0.88
1-Year Target Price5.19
Short Ratio6.51
Short % of Float14.80

Price Performance & Relative Strength

Period Price Performance Relative Strength
1 Week -1.14% 29 / 100   
1 Month -8.25% 22 / 100   
2 Months 2.12% 50 / 100   
6 Months 5.08% 54 / 100   
1 Year 31.52% 68 / 100   



Disclaimer - Privacy Policy - Terms Of Service - Cookie Use Policy - FAQ - Contact Us